316 related articles for article (PubMed ID: 23276886)
1. Clofarabine does not negatively impact the outcomes of patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation.
Mathisen MS; Kantarjian H; Jabbour E; Garcia-Manero G; Ravandi F; Faderl S; Borthakur G; Cortes JE; Quintás-Cardama A
Clin Lymphoma Myeloma Leuk; 2013 Apr; 13(2):139-43. PubMed ID: 23276886
[TBL] [Abstract][Full Text] [Related]
2. Clofarabine ± fludarabine with once daily i.v. busulfan as pretransplant conditioning therapy for advanced myeloid leukemia and MDS.
Andersson BS; Valdez BC; de Lima M; Wang X; Thall PF; Worth LL; Popat U; Madden T; Hosing C; Alousi A; Rondon G; Kebriaei P; Shpall EJ; Jones RB; Champlin RE
Biol Blood Marrow Transplant; 2011 Jun; 17(6):893-900. PubMed ID: 20946966
[TBL] [Abstract][Full Text] [Related]
3. Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients ≤60 years with newly diagnosed acute myeloid leukemia.
Nazha A; Kantarjian H; Ravandi F; Huang X; Choi S; Garcia-Manero G; Jabbour E; Borthakur G; Kadia T; Konopleva M; Cortes J; Ferrajoli A; Kornblau S; Daver N; Pemmaraju N; Andreeff M; Estrov Z; Du M; Brandt M; Faderl S
Am J Hematol; 2013 Nov; 88(11):961-6. PubMed ID: 23877926
[TBL] [Abstract][Full Text] [Related]
4. Control of relapsed or refractory acute myeloid leukemia by clofarabine in preparation for allogeneic stem cell transplant.
Loeffler C; Kapp M; Grigoleit GU; Mielke S; Loeffler J; Heuschmann PU; Malzahn U; Hupp E; Einsele H; Stuhler G
Leuk Lymphoma; 2015; 56(12):3365-9. PubMed ID: 26014275
[TBL] [Abstract][Full Text] [Related]
5. A randomized phase 2 study of idarubicin and cytarabine with clofarabine or fludarabine in patients with newly diagnosed acute myeloid leukemia.
Jabbour E; Short NJ; Ravandi F; Huang X; Xiao L; Garcia-Manero G; Plunkett W; Gandhi V; Sasaki K; Pemmaraju N; Daver NG; Borthakur G; Jain N; Konopleva M; Estrov Z; Kadia TM; Wierda WG; DiNardo CD; Brandt M; O'Brien SM; Cortes JE; Kantarjian H
Cancer; 2017 Nov; 123(22):4430-4439. PubMed ID: 28708931
[TBL] [Abstract][Full Text] [Related]
6. Cytoreductive treatment with clofarabine/ara-C combined with reduced-intensity conditioning and allogeneic stem cell transplantation in patients with high-risk, relapsed, or refractory acute myeloid leukemia and advanced myelodysplastic syndrome.
Buchholz S; Dammann E; Stadler M; Krauter J; Beutel G; Trummer A; Eder M; Ganser A
Eur J Haematol; 2012 Jan; 88(1):52-60. PubMed ID: 21883483
[TBL] [Abstract][Full Text] [Related]
7. The role of Clofarabine in the treatment of adults with acute myeloid leukemia.
Fozza C
Crit Rev Oncol Hematol; 2015 Mar; 93(3):237-45. PubMed ID: 25457773
[TBL] [Abstract][Full Text] [Related]
8. Long-Term Outcomes after Treatment with Clofarabine ± Fludarabine with Once-Daily Intravenous Busulfan as Pretransplant Conditioning Therapy for Advanced Myeloid Leukemia and Myelodysplastic Syndrome.
Alatrash G; Thall PF; Valdez BC; Fox PS; Ning J; Garber HR; Janbey S; Worth LL; Popat U; Hosing C; Alousi AM; Kebriaei P; Shpall EJ; Jones RB; de Lima M; Rondon G; Chen J; Champlin RE; Andersson BS
Biol Blood Marrow Transplant; 2016 Oct; 22(10):1792-1800. PubMed ID: 27377901
[TBL] [Abstract][Full Text] [Related]
9. Clofarabine in the treatment of newly diagnosed acute myeloid leukemia in older adults.
Tran H; Yang D
Ann Pharmacother; 2012 Jan; 46(1):89-96. PubMed ID: 22170975
[TBL] [Abstract][Full Text] [Related]
10. Clofarabine versus fludarabine-based reduced-intensity conditioning regimen prior to allogeneic transplantation in adults with AML/MDS.
Chevallier P; Labopin M; de La Tour RP; Lioure B; Bulabois CE; Huynh A; Blaise D; Turlure P; Daguindau E; Maillard N; Yakoub-Agha I; Guillerm G; Delage J; Contentin N; Bay JO; Beckerich F; Bourhis JH; Detrait M; Vigouroux S; François S; Legrand F; Guillaume T; Mohty M;
Cancer Med; 2016 Nov; 5(11):3068-3076. PubMed ID: 27748046
[TBL] [Abstract][Full Text] [Related]
11. Clofarabine plus low-dose cytarabine followed by clofarabine plus low-dose cytarabine alternating with decitabine in acute myeloid leukemia frontline therapy for older patients.
Faderl S; Ravandi F; Huang X; Wang X; Jabbour E; Garcia-Manero G; Kadia T; Ferrajoli A; Konopleva M; Borthakur G; Burger J; Feliu J; Kantarjian HM
Cancer; 2012 Sep; 118(18):4471-7. PubMed ID: 22282348
[TBL] [Abstract][Full Text] [Related]
12. Clofarabine combinations as acute myeloid leukemia salvage therapy.
Faderl S; Ferrajoli A; Wierda W; Huang X; Verstovsek S; Ravandi F; Estrov Z; Borthakur G; Kwari M; Kantarjian HM
Cancer; 2008 Oct; 113(8):2090-6. PubMed ID: 18756533
[TBL] [Abstract][Full Text] [Related]
13. Allo-SCT conditioning for myelodysplastic syndrome and acute myeloid leukemia with clofarabine, cytarabine and ATG.
Martin MG; Uy GL; Procknow E; Stockerl-Goldstein K; Cashen A; Westervelt P; Abboud CN; Augustin K; Luo J; DiPersio JF; Vij R
Bone Marrow Transplant; 2009 Jul; 44(1):13-7. PubMed ID: 19139740
[TBL] [Abstract][Full Text] [Related]
14. Randomized Phase II Study of Clofarabine-Based Consolidation for Younger Adults With Acute Myeloid Leukemia in First Remission.
Thomas X; de Botton S; Chevret S; Caillot D; Raffoux E; Lemasle E; Marolleau JP; Berthon C; Pigneux A; Vey N; Reman O; Simon M; Recher C; Cahn JY; Hermine O; Castaigne S; Celli-Lebras K; Ifrah N; Preudhomme C; Terré C; Dombret H
J Clin Oncol; 2017 Apr; 35(11):1223-1230. PubMed ID: 28221862
[TBL] [Abstract][Full Text] [Related]
15. Report of a phase II study of clofarabine and cytarabine in de novo and relapsed and refractory AML patients and in selected elderly patients at high risk for anthracycline toxicity.
Agura E; Cooper B; Holmes H; Vance E; Berryman RB; Maisel C; Li S; Saracino G; Tadic-Ovcina M; Fay J
Oncologist; 2011; 16(2):197-206. PubMed ID: 21273514
[TBL] [Abstract][Full Text] [Related]
16. Long-Term Follow-Up and Impact of Comorbidity before Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Relapsed or Refractory Acute Myeloid Leukemia-Lessons Learned from the Prospective BRIDGE Trial.
Middeke JM; Herbst R; Parmentier S; Bug G; Hänel M; Stuhler G; Schäfer-Eckart K; Rösler W; Klein S; Bethge W; Bitz U; Büttner B; Knoth H; Alakel N; Schaich M; Morgner A; Kramer M; Sockel K; von Bonin M; Stölzel F; Platzbecker U; Röllig C; Thiede C; Ehninger G; Bornhäuser M; Schetelig J
Biol Blood Marrow Transplant; 2017 Sep; 23(9):1491-1497. PubMed ID: 28527985
[TBL] [Abstract][Full Text] [Related]
17. Sequential regimen of clofarabine, cytosine arabinoside and reduced-intensity conditioned transplantation for primary refractory acute myeloid leukemia.
Mohty M; Malard F; Blaise D; Milpied N; Socié G; Huynh A; Reman O; Yakoub-Agha I; Furst S; Guillaume T; Tabrizi R; Vigouroux S; Peterlin P; El-Cheikh J; Moreau P; Labopin M; Chevallier P
Haematologica; 2017 Jan; 102(1):184-191. PubMed ID: 27561720
[TBL] [Abstract][Full Text] [Related]
18. Clofarabine salvage therapy before allogeneic hematopoietic stem cell transplantation in patients with relapsed or refractory AML: results of the BRIDGE trial.
Middeke JM; Herbst R; Parmentier S; Bug G; Hänel M; Stuhler G; Schäfer-Eckart K; Rösler W; Klein S; Bethge W; Bitz U; Büttner B; Knoth H; Alakel N; Schaich M; Morgner A; Kramer M; Sockel K; von Bonin M; Stölzel F; Platzbecker U; Röllig C; Thiede C; Ehninger G; Bornhäuser M; Schetelig J
Leukemia; 2016 Feb; 30(2):261-7. PubMed ID: 26283567
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic value of clofarabine in younger and middle-aged (18-65 years) adults with newly diagnosed AML.
Löwenberg B; Pabst T; Maertens J; van Norden Y; Biemond BJ; Schouten HC; Spertini O; Vellenga E; Graux C; Havelange V; de Greef GE; de Weerdt O; Legdeur MJ; Kuball J; Kooy MV; Gjertsen BT; Jongen-Lavrencic M; van de Loosdrecht AA; van Lammeren-Venema D; Hodossy B; Breems DA; Chalandon Y; Passweg J; Valk PJ; Manz MG; Ossenkoppele GJ;
Blood; 2017 Mar; 129(12):1636-1645. PubMed ID: 28049642
[TBL] [Abstract][Full Text] [Related]
20. Results from a clofarabine-busulfan-containing, reduced-toxicity conditioning regimen prior to allogeneic stem cell transplantation: the phase 2 prospective CLORIC trial.
Chevallier P; Labopin M; Socié G; Tabrizi R; Furst S; Lioure B; Guillaume T; Delaunay J; de La Tour RP; Vigouroux S; El-Cheikh J; Blaise D; Michallet M; Bilger K; Milpied N; Moreau P; Mohty M
Haematologica; 2014 Sep; 99(9):1486-91. PubMed ID: 24951467
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
